To assess the differences in permanent morphologic and functional damage between nimodipine and placebo-treated stroke patients.
- Nimodipine (Nimotop®)Drug
Intervention Desc: Calcium channel blocker (L-type calcium channels)
Randomized, double-blind, placebo-controlled study of 27 patients.
Patients were randomized to receive intravenous nimodipine, 1 mg/hr in first 2 hours, 2 mg/hr next 5 days, followed by 30 mg oral qid. day 6-21 or an identical regimen of placebo. All patients were treated with low molecular weight dextran (500 ml/day for 15 days) and glycerol (10% for 5 days).
|Type||Measure||Time Frame||Safety Issue|
|Primary||Mathew Score on admission and at 3 weeks, Barthel Index at 21 days and 6 months, FDG PET on the day of admission and at 21 days.|